Novel Cation-Exchange Wound Dressing for Diabetic Ulcers

用于糖尿病溃疡的新型阳离子交换伤口敷料

• 批准号: 6834243
• 负责人: DAVID J VACHON
• 金额: $ 10.84万
• 依托单位: AEGIS BIOSCIENCES, LLC
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-30 至 2006-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6834243
• 关键词: amputation; angiogenesis; antibiotics; biomaterial development /preparation; biomaterial evaluation; biotechnology; cations; diabetes mellitus therapy; disease /disorder model; disease /disorder proneness /risk; drug delivery systems; fluid; foot; health care cost /financing; laboratory rat; nitric oxide; nonhuman therapy evaluation; polyethylene glycols; polymers; protease inhibitor; therapy design /development; ulcer; ultraviolet spectrometry; wound healing; wound infection

DESCRIPTION (provided by applicant): As many as 20 million people in the United States have diabetes and more than two million of these individuals will develop diabetic foot ulcers during their lifetime. In addition, the incidence of ulcer recurrence after complete healing approaches 30% within 12 months. The average cost for a single episode of a diabetic foot ulcer has been reported to be $4,595. Diabetic foot ulcers are very difficult to heal and represent a serious problem in this country. They are also a leading cause of hospitalization among those with diabetes. At any given time, up to 800,000 people in the U.S. suffer from them and these patients are at higher risk for infection, as well as amputation, with roughly 67,000 (diabetes-related) amputations conducted each year. Diabetic foot disease is estimated to cost the nation in excess of $1.2 billion [US] each year, excluding the costs of surgery, rehabilitation, prostheses, and lost income. It is clear that despite the medical advances that have been made in the treatment of diabetes in the past fifty years, there remains a significant need for more effective therapies to treat diabetic foot disease. With costs to treat these wounds reaching into the billions of dollars annually and rising, what is needed is a treatment that makes use of the fundamental understanding of (1) the underlying biology and biochemistry of these wounds and their mitigation, and application of this knowledge to (2) biomaterials science and controlled release technology, thus allowing for the treatment of these wounds in a rational & scientific manner. Furthermore, the treatment should provide a cost-conscious alternative to today's (expensive) therapies that in addition, relieves suffering for these "hard-to-hear' patients, and provides better overall patient outcomes. The development of a cost-effective, non-adherent novel hydrogel dressing that will remove fluid from the wound, add a low dose proteinase inhibitor and antibiotic, and/or nitric oxide precursor and angiogenic agent, and in addition acts to minimize noxious wound biomolecules by sequestration is described.

描述（由申请人提供）： 在美国，有多达2000万人患有糖尿病，其中超过200万人将在其一生中患糖尿病足溃疡。此外，完全愈合后的溃疡复发发生率在12个月内接近30％。据报道，单个糖尿病足溃疡的平均成本为4,595美元。在这个国家，糖尿病足溃疡很难治愈，并且代表了一个严重的问题。它们也是糖尿病患者住院的主要原因。在任何给定的时间，美国最多有80万人患有障碍，并且这些患者的感染风险较高，并且截肢的风险较高，每年进行大约67,000（与糖尿病有关的）截肢。据估计，糖尿病足病估计每年损失超过12亿美元的美国，不包括手术，康复，假体和收入损失的费用。显然，尽管在过去五十年中治疗糖尿病方面取得了进展，但仍需要更有效的疗法治疗糖尿病足病。由于需要治疗这些伤口每年数十亿美元和上升的费用，需要的是一种治疗方法，它利用了对（1）这些伤口的基本生物学和生物化学的基本理解及其缓解措施，并将这些知识应用于（2）生物材料科学和受控技术，从而可以治疗这些伤口，从而使这些受伤的人以这些理性的科学和科学的方式来治疗。 Furthermore, the treatment should provide a cost-conscious alternative to today's (expensive) therapies that in addition, relieves suffering for these "hard-to-hear' patients, and provides better overall patient outcomes. The development of a cost-effective, non-adherent novel hydrogel dressing that will remove fluid from the wound, add a low dose proteinase inhibitor and antibiotic, and/or nitric oxide precursor and angiogenic agent, and in addition描述了通过隔离来最大程度地减少有害伤口生物分子的作用。